Rifampicin for Cholestatic Pruritus
Rifampicin should be initiated at 150 mg daily as second-line therapy for cholestatic pruritus after failure of bile acid sequestrants, with mandatory monitoring of liver function tests and stepwise dose escalation up to a maximum of 600 mg daily. 1
Positioning in Treatment Algorithm
Rifampicin is established as second-line therapy for cholestatic pruritus across all cholestatic liver diseases including Alagille syndrome, PFIC types 1-3, and primary biliary cholangitis 2, 1. It should only be initiated after:
- First-line bile acid sequestrants (cholestyramine 4g up to four times daily) have failed or are not tolerated
- The sequestrants must be spaced at least 4 hours away from other medications 1
The mechanism likely involves PXR (pregnane X receptor) activation, leading to detoxification of bile acids and other pruritogens 2, 1.
Dosing Protocol
Starting dose: 150 mg daily 1
Dose escalation: If no benefit is observed, increase stepwise (typically every 2 weeks) to a maximum of 600 mg daily 1
Pediatric dosing: 10-20 mg/kg/day in two divided doses 3
The evidence shows moderate efficacy with 74% response rates in pediatric cholestasis 3 and 51% response rates (complete or partial) in mixed pediatric populations 4.
Mandatory Monitoring Requirements
Critical hepatotoxicity risk: Drug-induced hepatitis and significant liver dysfunction occur in up to 12% of cholestatic patients after 2-3 months of treatment 1
Monitoring protocol:
- Baseline liver function tests before initiation
- Weekly serum liver tests during dose escalation 1
- Continue regular monitoring throughout treatment
- Discontinue immediately if hepatotoxicity develops
This monitoring is non-negotiable given the substantial hepatotoxicity risk in an already compromised liver population.
Contraindications
Absolute contraindications 5:
- Hypersensitivity to rifampin or any rifamycins
- Concurrent use with ritonavir-boosted saquinavir (severe hepatocellular toxicity risk)
- Concurrent use with atazanavir, darunavir, fosamprenavir, saquinavir, or tipranavir (loss of antiviral efficacy)
- Concurrent praziquantel therapy (rifampin must be stopped 4 weeks before praziquantel)
Relative caution:
- Diabetes mellitus (may complicate glucose management) 5
- Pregnancy (use alternative approaches)
Duration and Efficacy
Ongoing efficacy is documented for up to 2 years of continuous treatment 1. In benign recurrent intrahepatic cholestasis (BRIC), rifampicin can be used episodically during attacks with excellent results—shortening attack duration and reducing complications 6.
Predictors of response: Patients with normal or only slightly elevated gamma-glutamyl transpeptidase (GGT) levels show better responses, with some achieving complete biochemical remission 7. Low baseline GGT predicts good outcomes 8.
Critical Patient Counseling
Patients must be warned about 5:
- Discoloration of urine, tears, sweat, sputum, and teeth (yellow, orange, red, brown)
- Permanent staining of soft contact lenses
- Reduced efficacy of oral contraceptives—alternative contraception is mandatory
- Take on empty stomach (1 hour before or 2 hours after meals) with full glass of water
Common Pitfalls to Avoid
Premature escalation to third-line agents: The 2009 EASL guidelines emphasize "the importance of fully exploring the use of cholestyramine and rifampicin therapy" before resorting to naltrexone or sertraline, as clinical experience with these agents has been disappointing 1
Intermittent dosing: Rifampicin is NOT recommended for intermittent therapy—daily dosing is essential to avoid rare renal hypersensitivity reactions upon resumption 5
Inadequate monitoring: The 12% hepatotoxicity rate in cholestatic patients makes weekly monitoring during titration essential, not optional
Drug interactions: Rifampicin is a potent enzyme inducer affecting numerous medications—review all concurrent drugs before initiation 5
When to Abandon Rifampicin
If no benefit occurs at maximum dose (600 mg daily) or if intolerance develops, proceed to third-line therapy with naltrexone (starting 25 mg, up to 50 mg daily) 1. Fourth-line is sertraline (up to 100 mg daily), followed by experimental approaches or referral to specialized centers 1.